Earnings summaries and quarterly performance for Cytek Biosciences.
Executive leadership at Cytek Biosciences.
Board of directors at Cytek Biosciences.
Research analysts who have asked questions during Cytek Biosciences earnings calls.
David Westenberg
Piper Sandler
8 questions for CTKB
Also covers: ADPT, AKYA, BLLN +14 more
CW
Chad Wiatrowski
TD Cowen
7 questions for CTKB
Also covers: BLFS, CDXS, MASS +4 more
Harrison Parsons
Stephens
6 questions for CTKB
Also covers: CUTR, HOLX, PACB
Noah Lewis
Raymond James
6 questions for CTKB
Also covers: OSUR
Andrew Cooper
Raymond James
4 questions for CTKB
Also covers: AZTA, CDNA, EXAS +12 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
3 questions for CTKB
Also covers: ABCL, ABSI, ARWR +20 more
Ben Mee
Stephens
2 questions for CTKB
Also covers: VCYT
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for CTKB
Also covers: A, ADPT, AVTR +21 more
SG
Skye Gilbert
Piper Sandler
2 questions for CTKB
TS
Tejas Savant
Morgan Stanley
2 questions for CTKB
Also covers: ADPT, AKYA, AVTR +19 more
MC
Mason Carrico
Stephens Inc.
1 question for CTKB
Also covers: AKYA, CDNA, CSTL +13 more
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for CTKB
Also covers: CRL, MRVI, NTRA +4 more
YT
Yih-Ming Tu
Morgan Stanley
1 question for CTKB
Also covers: CYRX
Recent press releases and 8-K filings for CTKB.
Cytek Biosciences Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
CTKB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cytek Biosciences reported Q4 2025 revenue of $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue historically achieved. Full year 2025 revenue reached $201.5 million, up 1% compared to 2024, with accelerating growth quarter-over-quarter.
- For the full year 2025, recurring revenue grew 21% year-over-year and represented 34% of total revenue. Reagent revenue also grew more than 25% for the full year.
- The company reported a GAAP net loss of $44.1 million in Q4 2025, which included a $38.1 million valuation allowance against deferred tax assets. Full year 2025 Adjusted EBITDA was $5 million.
- Cytek Biosciences initiated its 2026 revenue outlook at $205 million-$212 million, reflecting an improved market environment and continued growth in APAC, service, and reagent businesses.
1 day ago
Cytek Biosciences Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
CTKB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cytek Biosciences reported Q4 2025 revenue of $62.1 million, an 8% year-over-year increase, marking its highest quarterly revenue historically, contributing to a full year 2025 revenue of $201.5 million, up 1% from 2024. The company experienced accelerating revenue growth quarter-over-quarter throughout 2025, with Q4 showing the strongest growth.
- The company recorded a net loss of $44.1 million in Q4 2025, primarily due to a $38.1 million non-cash valuation allowance against deferred tax assets. Adjusted EBITDA for Q4 2025 was $4.5 million, and for the full year 2025, it was $5 million.
- Recurring revenue grew 21% year-over-year in 2025, accounting for 34% of total revenue, with service revenue growing 25% in Q4 2025.
- For 2026, Cytek Biosciences projects revenue to be between $205 million and $212 million, based on constant currency exchange rates.
- The company ended 2025 with $261.5 million in cash, cash equivalents, and marketable securities and repurchased $15.1 million of its stock during the year.
1 day ago
Cytek Biosciences Reports Q4 and Full Year 2025 Financial Results
CTKB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cytek Biosciences reported Q4 2025 revenue of $62.1 million, an 8% increase year-over-year, and full-year 2025 revenue of $201.5 million, a 1% increase year-over-year.
- The company posted a Q4 2025 net loss of $44.1 million, which included a $38.1 million non-cash valuation allowance against deferred tax assets. Excluding this allowance, the net loss would have been $6.0 million.
- Adjusted EBITDA for Q4 2025 declined to $4.5 million from $12.5 million in the prior year quarter, and full-year 2025 Adjusted EBITDA was $5 million, down from $22.4 million in 2024.
- Recurring revenue grew 21% year-over-year in 2025, representing 34% of total revenue, and the company ended 2025 with $261.5 million in cash and marketable securities.
- For full-year 2026, Cytek Biosciences initiated revenue guidance of $205 million-$212 million.
1 day ago
Cytek Biosciences Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook
CTKB
Earnings
Guidance Update
Product Launch
- Cytek Biosciences reported total revenue of $62.1 million for the fourth quarter of 2025, an 8% increase compared to the fourth quarter of 2024, and $201.5 million for the full year 2025, a 1% increase over the full year 2024.
- The company recorded a net loss of $44.1 million in Q4 2025 and a net loss of $66.5 million for the full year 2025. Adjusted EBITDA for full year 2025 was $5.0 million, a decrease from $22.4 million in 2024.
- For fiscal year 2026, Cytek Biosciences initiated revenue guidance in the range of $205 million to $212 million, projecting 2% to 5% growth over full year 2025.
- In 2025, the company launched the Cytek Aurora Evo system and the Cytek Muse Micro cell analyzer, and repurchased approximately 3.3 million shares for $15.1 million.
1 day ago
Cytek Biosciences Reports Q4 and Full Year 2025 Financial Results, Provides 2026 Outlook
CTKB
Earnings
Guidance Update
Share Buyback
- Cytek Biosciences reported total revenue of $62.1 million for Q4 2025, an 8% increase compared to Q4 2024 and the highest quarterly revenue historically. Full-year 2025 total revenue was $201.5 million, a 1% increase over 2024.
- For the full year 2025, the company recorded a net loss of $66.5 million, compared to a net loss of $6.0 million in 2024, and Adjusted EBITDA decreased to $5.0 million from $22.4 million in 2024.
- Recurring revenue grew 21% in 2025, reaching 34% of total revenue, and the company expanded its installed instrument base to 3,664 with 630 new placements during the year.
- Cytek Biosciences initiated its 2026 revenue guidance to be in the range of $205 million to $212 million, representing 2% to 5% growth over full year 2025.
- The company repurchased approximately 3.3 million shares for $15.1 million during 2025, with cash and marketable securities totaling $261.5 million as of December 31, 2025.
1 day ago
Cytek Provides Preliminary 2025 Revenue Estimates and 2026 Growth Drivers
CTKB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cytek estimates its 2025 total revenue to be approximately $201 million and reported $262 million in cash and marketable securities.
- For Q4 2025, the company reported preliminary product revenue of $38.1 million and service revenue of $14.2 million, noting a meaningful acceleration in year-over-year quarterly revenue growth compared to prior quarters in 2025.
- Cytek's 2025 operational highlights include 3,456 units placed, serving over 2,000 customers across more than 70 countries, and its Cytek Cloud platform grew to over 22,600 users.
- Key growth drivers for 2026 include growth in the installed base to drive service revenue, growth in reagents, innovative new products, and clinical expansion in EMEA and China.
Jan 15, 2026, 1:15 AM
Cytek Reports Preliminary 2025 Results and Strategic Outlook at JPMorgan Conference
CTKB
Revenue Acceleration/Inflection
Share Buyback
M&A
- Cytek reported preliminary full-year 2025 revenue of $201 million and Q4 2025 revenue of $62 million, with year-over-year revenue growth accelerating from -8% in Q1 2025 to 8% in Q4 2025.
- The company's revenue growth is primarily attributed to taking market share from competitors, even in a challenging market, and has seen demand stabilization in the U.S. and Europe in Q3 and Q4 2025, which is expected to continue into 2026.
- Recurring revenue from services and reagents, along with APAC instrument revenue, constitutes 50% of the overall business and experienced multi-double-digit growth in 2025, with reagent revenue growing more than 20%.
- Cytek maintains a balanced capital allocation strategy, sizing share repurchases in 2025 to approximately equal free cash flow, and is one of the few life science tool companies generating positive cash flow.
Jan 15, 2026, 1:15 AM
Cytek Biosciences Reports Preliminary 2025 Results and Outlines Growth Strategy
CTKB
Revenue Acceleration/Inflection
Share Buyback
New Projects/Investments
- Cytek Biosciences reported preliminary full-year 2025 revenue of $201 million, with Q4 2025 revenue at $62 million, representing an 8% year-over-year growth and a return to positive growth after earlier declines.
- The company's recent revenue growth is primarily driven by gaining market share from competitors, and management expects this positive momentum to continue, leading to substantial growth in 2026.
- Cytek identifies a significant opportunity in the reagent market, estimating $150 million per year in non-Cytek reagents currently used in its over 3,000 installed instruments. Reagent revenue grew over 20% in 2025, with plans to further invest in sales and marketing for reagents.
- Cytek maintains a balanced capital allocation strategy, aiming for share repurchases approximately equal to its free cash flow while also pursuing opportunistic M&A.
Jan 15, 2026, 1:15 AM
Cytek Biosciences Reports 2025 Revenue and Outlines Growth Strategy
CTKB
Revenue Acceleration/Inflection
Product Launch
M&A
- Cytek Biosciences reported $201 million in revenue for 2025, with Q4 2025 revenue reaching $62 million, representing an 8% year-over-year growth and an acceleration from earlier quarters.
- The company's growth is primarily attributed to gaining market share within a cell analysis market projected to reach $9.2 billion by 2032 with an 8.8% CAGR.
- Cytek leverages an installed base of over 3,000 instruments globally to drive recurring revenue, with reagent revenue growing over 20% in 2025.
- Key growth drivers include new product launches in 2025, such as the Aurora Evo and Guava Muse, and the expansion of the Cytek Cloud user base by over 40% by Q3 2025.
- Cytek maintains a balanced capital allocation strategy, including share repurchases approximately equal to free cash flow and opportunistic M&A, and is one of the few life science tool companies generating positive cash flow.
Jan 15, 2026, 1:15 AM
Cytek Biosciences Announces Preliminary Q4 and Full Year 2025 Revenue Results
CTKB
Earnings
Revenue Acceleration/Inflection
- Cytek Biosciences, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.
- The company expects total revenue for full year 2025 to be approximately $201 million.
- Fourth quarter 2025 revenue is expected to be approximately $62 million, representing 8% growth compared to Q4 2024 and 19% growth compared to Q3 2025.
- The CEO highlighted a meaningful acceleration of growth in Q4 2025, driven by strong growth in Services, Reagents, and Asia Pacific instrument revenue, and improved instrument revenue growth in the US and EMEA.
Jan 13, 2026, 9:11 PM
Quarterly earnings call transcripts for Cytek Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more